AIkido Pharma (NASDAQ:AIKI) and OneMedNet (NASDAQ:ONMD) Head to Head Contrast

AIkido Pharma (NASDAQ:AIKI) and OneMedNet (NASDAQ:ONMD) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, earnings, dividends, institutional ownership, profitability and analyst recommendations.

Analyst Ratings

This is a summary of current ratings and price targets for AIkido Pharma and OneMedNet, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AIkido Pharma	0	0	0	0	N/A
OneMedNet	0	0	0	0	N/A

Risk & Volatility

AIkido Pharma has a beta of 0.93, indicating that its share price is 7% less volatile than the S&P 500. Comparatively, OneMedNet has a beta of 0.75, indicating that its share price is 25% less volatile than the S&P 500.

Earnings and Valuation

This table compares AIkido Pharma and OneMedNet”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AIkido Pharma	$10,000.00	1,053.12	-$7.17 million	($3.88)	-0.49
OneMedNet	$1.02 million	17.90	-$23.20 million	($0.19)	-4.04

AIkido Pharma has higher earnings, but lower revenue than OneMedNet. OneMedNet is trading at a lower price-to-earnings ratio than AIkido Pharma, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares AIkido Pharma and OneMedNet’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
AIkido Pharma	N/A	-18.21%	-16.94%
OneMedNet	N/A	N/A	-116.74%

Insider & Institutional Ownership

10.9% of AIkido Pharma shares are owned by institutional investors. Comparatively, 0.9% of OneMedNet shares are owned by institutional investors. 8.6% of AIkido Pharma shares are owned by insiders. Comparatively, 45.7% of OneMedNet shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

AIkido Pharma beats OneMedNet on 6 of the 10 factors compared between the two stocks.

About AIkido Pharma

AIkido Pharma Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, University of Maryland Baltimore, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as Spherix Incorporated and changed its name to AIkido Pharma Inc. in March 2021. AIkido Pharma Inc. was founded in 1967 and is headquartered in New York, New York.

About OneMedNet

OneMedNet Corporation provides clinical imaging solutions. It offers iRWD, a solution that utilizes AI to securely de-identify, search, and curate imaging data for its partner network consisting of medical and academic research institutions to generate progression in stages of medical research, discovery and diagnostics that span the field of life sciences. OneMedNet Corporation is based in Eden Prairie, Minnesota.